Cohesin Is Required for Activation of MYC by Estradiol

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  McEwan, Miranda V ^a   Eccles, Michael R ^a   Horsfield, Julia A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COHESIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MYC PROTEIN; PROTEIN P2; PROTEIN RAD21; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE LOCUS; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; ONCOGENE MYC; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN DNA BINDING; RECEPTOR BINDING; REGULATORY SEQUENCE; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CHROMATIDS; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA REPLICATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION; GENES, MYC; HUMANS; MCF-7 CELLS; NUCLEAR PROTEINS; ONCOGENE PROTEIN P55(V-MYC); PHOSPHOPROTEINS; PROTEIN BINDING; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION;

EID: 84869053071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049160     Document Type: Article

References (109)

1. Felsher DW, (2010) MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer 1: 597-604.
2. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, et al. (2003) Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
3. Liu Q, Yang Y, Li Y, Zhang Z, (2011) Global and threshold-free Transcriptional Regulatory Networks reconstruction through integrating ChIP-Chip and expression data. Curr Protein Pept Sci 12: 631-642.
4. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, et al. (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 103: 17834-17839.
5. Kelly K, Siebenlist U, (1985) The role of c-myc in the proliferation of normal and neoplastic cells. J Clin Immunol 5: 65-77.
6. Peiro-Jordan R, Krishna-Subramanian S, Hanski ML, Luscher-Firzlaff J, Zeitz M, et al. (2012) The chemopreventive agent ursodeoxycholic acid inhibits proliferation of colon carcinoma cells by suppressing c-Myc expression. Eur J Cancer Prev 21: 413-422.
7. Wu N, Rollin J, Masse I, Lamartine J, Gidrol X, (2012) p63 regulates human keratinocyte proliferation via MYC-regulated gene network and differentiation commitment through cell adhesion-related gene network. J Biol Chem 287: 5627-5638.
8. Aguda BD, Kim Y, Kim HS, Friedman A, Fine HA, (2011) Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation. Biophys J 101: 2082-2091.
9. Huang R, Cheung NK, Vider J, Cheung IY, Gerald WL, et al. (2011) MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J 25: 4138-4149.
10. Hoffman B, Liebermann DA, Selvakumaran M, Nguyen HQ, (1996) Role of c-myc in myeloid differentiation, growth arrest and apoptosis. Curr Top Microbiol Immunol 211: 17-27.
11. Romero OA, Setien F, John S, Gimenez-Xavier P, Gomez-Lopez G, et al. (2012) The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol Med 4: 603-616.
12. Leoni BD, Natoli M, Nardella M, Bucci B, Zucco F, et al. (2012) Differentiation of Caco-2 cells requires both transcriptional and post-translational down-regulation of Myc. Differentiation 83: 116-127.
13. Batliner J, Buehrer E, Federzoni EA, Jenal M, Tobler A, et al. (2012) Transcriptional regulation of MIR29B by PU.1 (SPI1) and MYC during neutrophil differentiation of acute promyelocytic leukaemia cells. Br J Haematol 157: 270-274.
14. Uribesalgo I, Buschbeck M, Gutierrez A, Teichmann S, Demajo S, et al. (2011) E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol 13: 1443-1449.
15. Hoffman B, Liebermann DA, (1998) The proto-oncogene c-myc and apoptosis. Oncogene 17: 3351-3357.
16. Hogstrand K, Hejll E, Sander B, Rozell B, Larsson LG, et al. (2012) Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia. PLoS One 7: e31366.
17. Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, et al. (2012) Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene.
18. Jarvinen K, Hotti A, Santos L, Nummela P, Holtta E, (2011) Caspase-8, c-FLIP, and caspase-9 in c-Myc-induced apoptosis of fibroblasts. Exp Cell Res 317: 2602-2615.
19. Liu H, Radisky DC, Yang D, Xu R, Radisky ES, et al. (2012) MYC suppresses cancer metastasis by direct transcriptional silencing of alphav and beta3 integrin subunits. Nat Cell Biol 14: 567-574.
20. Wolfer A, Ramaswamy S, (2011) MYC and metastasis. Cancer Res 71: 2034-2037.
21. Almeida MI, Reis RM, Calin GA, (2010) MYC-microRNA-9-metastasis connection in breast cancer. Cell Res 20: 603-604.
22. Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, et al. (2009) MYC is a metastasis gene for non-small-cell lung cancer. PLoS One 4: e6029.
23. Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, et al. (1987) Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 56: 251-259.
24. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, et al. (2012) Transcriptional Amplification in Tumor Cells with Elevated c-Myc. Cell 151: 56-67.
25. Nie Z, Hu G, Wei G, Cui K, Yamane A, et al. (2012) c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells. Cell 151: 68-79.
26. Hynes NE, Stoelzle T, (2009) Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res 11: 210.
27. Abuli A, Bessa X, Gonzalez JR, Ruiz-Ponte C, Caceres A, et al. (2010) Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype. Gastroenterology 139: 788-796, 796 e781-786.
28. Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, et al. (2010) 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A 107: 9742-9746.
29. Okobia MN, Zmuda JM, Ferrell RE, Patrick AL, Bunker CH, (2011) Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry. Prostate 71: 1054-1063.
30. Beebe-Dimmer JL, Levin AM, Ray AM, Zuhlke KA, Machiela MJ, et al. (2008) Chromosome 8q24 markers: risk of early-onset and familial prostate cancer. Int J Cancer 122: 2876-2879.
31. Berndt SI, Potter JD, Hazra A, Yeager M, Thomas G, et al. (2008) Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet 17: 2665-2672.
32. Fletcher O, Johnson N, Gibson L, Coupland B, Fraser A, et al. (2008) Association of genetic variants at 8q24 with breast cancer risk. Cancer Epidemiol Biomarkers Prev 17: 702-705.
33. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42: 874-879.
34. Neta G, Yu CL, Brenner A, Gu F, Hutchinson A, et al. (2012) Common genetic variants in the 8q24 region and risk of papillary thyroid cancer. Laryngoscope 122: 1040-1042.
35. Stoelzle T, Schwarb P, Trumpp A, Hynes NE, (2009) c-Myc affects mRNA translation, cell proliferation and progenitor cell function in the mammary gland. BMC Biol 7: 63.
36. Dubik D, Shiu RP, (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263: 12705-12708.
37. Dubik D, Dembinski TC, Shiu RP, (1987) Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47: 6517-6521.
38. Chen Y, Olopade OI, (2008) MYC in breast tumor progression. Expert Rev Anticancer Ther 8: 1689-1698.
39. Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, et al. (2009) Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One 4: e4710.
40. Musgrove EA, Sergio CM, Anderson LR, Inman CK, McNeil CM, et al. (2008) Identification of downstream targets of estrogen and c-myc in breast cancer cells. Adv Exp Med Biol 617: 445-451.
41. Schaaf CA, Misulovin Z, Sahota G, Siddiqui AM, Schwartz YB, et al. (2009) Regulation of the Drosophila Enhancer of split and invected-engrailed gene complexes by sister chromatid cohesion proteins. PLoS One 4: e6202.
42. Rhodes JM, Bentley FK, Print CG, Dorsett D, Misulovin Z, et al. (2010) Positive regulation of c-Myc by cohesin is direct, and evolutionarily conserved. Dev Biol 344: 637-649.
43. Kawauchi S, Calof AL, Santos R, Lopez-Burks ME, Young CM, et al. (2009) Multiple organ system defects and transcriptional dysregulation in the Nipbl(+/-) mouse, a model of Cornelia de Lange Syndrome. PLoS Genet 5: e1000650.
44. Remeseiro S, Cuadrado A, Gomez-Lopez G, Pisano DG, Losada A, (2012) A unique role of cohesin-SA1 in gene regulation and development. EMBO J 31: 2090-2102.
45. Liu J, Zhang Z, Bando M, Itoh T, Deardorff MA, et al. (2009) Transcriptional dysregulation in NIPBL and cohesin mutant human cells. PLoS Biol 7: e1000119.
46. Dorsett D, Strom L, (2012) The ancient and evolving roles of cohesin in gene expression and DNA repair. Curr Biol 22: R240-250.
47. Nasmyth K, Haering CH, (2009) Cohesin: its roles and mechanisms. Annu Rev Genet 43: 525-558.
48. Pauli A, van Bemmel JG, Oliveira RA, Itoh T, Shirahige K, et al. (2010) A direct role for cohesin in gene regulation and ecdysone response in Drosophila salivary glands. Curr Biol 20: 1787-1798.
49. Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, et al. (2010) Mediator and cohesin connect gene expression and chromatin architecture. Nature 467: 430-435.
50. Schmidt D, Schwalie PC, Ross-Innes CS, Hurtado A, Brown GD, et al. (2010) A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 20: 578-588.
51. Nativio R, Wendt KS, Ito Y, Huddleston JE, Uribe-Lewis S, et al. (2009) Cohesin is required for higher-order chromatin conformation at the imprinted IGF2-H19 locus. PLoS Genet 5: e1000739.
52. Hadjur S, Williams LM, Ryan NK, Cobb BS, Sexton T, et al. (2009) Cohesins form chromosomal cis-interactions at the developmentally regulated IFNG locus. Nature 460: 410-413.
53. Hou C, Dale R, Dean A, (2010) Cell type specificity of chromatin organization mediated by CTCF and cohesin. Proc Natl Acad Sci U S A 107: 3651-3656.
54. Hakimi MA, Bochar DA, Schmiesing JA, Dong Y, Barak OG, et al. (2002) A chromatin remodelling complex that loads cohesin onto human chromosomes. Nature 418: 994-998.
55. Rhodes JM, McEwan M, Horsfield JA, (2011) Gene regulation by cohesin in cancer: is the ring an unexpected party to proliferation? Mol Cancer Res 9: 1587-1607.
56. Sehl ME, Langer LR, Papp JC, Kwan L, Seldon JL, et al. (2009) Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer. Clin Cancer Res 15: 2192-2203.
57. Atienza JM, Roth RB, Rosette C, Smylie KJ, Kammerer S, et al. (2005) Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol Cancer Ther 4: 361-368.
58. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
59. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, et al. (2012) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A 109: 2730-2735.
60. Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, et al. (2011) High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A 108: 2058-2063.
61. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, et al. (2012) Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A 109: 9545-9550.
62. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, et al. (2009) An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462: 58-64.
63. Li G, Ruan X, Auerbach RK, Sandhu KS, Zheng M, et al. (2012) Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 148: 84-98.
64. Misulovin Z, Schwartz YB, Li XY, Kahn TG, Gause M, et al. (2008) Association of cohesin and Nipped-B with transcriptionally active regions of the Drosophila melanogaster genome. Chromosoma 117: 89-102.
65. Santos GF, Scott GK, Lee WM, Liu E, Benz C, (1988) Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. J Biol Chem 263: 9565-9568.
66. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, et al. (2008) Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 3: e2987.
67. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL, (2002) Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 62: 3126-3131.
68. Venditti M, Iwasiow B, Orr FW, Shiu RP, (2002) C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 99: 35-42.
69. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, et al. (2011) A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. Clin Cancer Res 17: 2024-2034.
70. Fullwood MJ, Ruan Y, (2009) ChIP-based methods for the identification of long-range chromatin interactions. J Cell Biochem 107: 30-39.
71. Sotelo J, Esposito D, Duhagon MA, Banfield K, Mehalko J, et al. (2010) Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A 107: 3001-3005.
72. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, et al. (2009) The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet 41: 885-890.
73. Wasserman NF, Aneas I, Nobrega MA, (2010) An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 20: 1191-1197.
74. Wright JB, Brown SJ, Cole MD, (2010) Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 30: 1411-1420.
75. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, et al. (2009) Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet 5: e1000597.
76. Zhang D, Jiang P, Xu Q, Zhang X, (2011) Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth. J Biol Chem 286: 17746-17754.
77. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, et al. (2011) Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473: 43-49.
78. Miller TL, Huzel NJ, Davie JR, Murphy LC, (1993) C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells. Mol Cell Endocrinol 91: 83-89.
79. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
80. Tuupanen S, Yan J, Turunen M, Gylfe AE, Kaasinen E, et al. (2012) Characterization of the colorectal cancer-associated enhancer MYC-335 at 8q24: the role of rs67491583. Cancer Genet 205: 25-33.
81. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
82. Riaz M, Berns EM, Sieuwerts AM, Ruigrok-Ritstier K, de Weerd V, et al. (2012) Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Res Treat 133: 843-851.
83. Wokolorczyk D, Gliniewicz B, Sikorski A, Zlowocka E, Masojc B, et al. (2008) A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 68: 9982-9986.
84. Tuupanen S, Niittymaki I, Nousiainen K, Vanharanta S, Mecklin JP, et al. (2008) Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. Cancer Res 68: 14-17.
85. Haiman CA, Le Marchand L, Yamamato J, Stram DO, Sheng X, et al. (2007) A common genetic risk factor for colorectal and prostate cancer. Nat Genet 39: 954-956.
86. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39: 645-649.
87. Dai J, Gu J, Huang M, Eng C, Kopetz ES, et al. (2012) GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33: 1327-1331.
88. Guo Y, Fang J, Liu Y, Sheng HH, Zhang XY, et al. (2011) Association between polymorphism rs6983267 and gastric cancer risk in Chinese population. World J Gastroenterol 17: 1759-1765.
89. Papanikolopoulou A, Landt O, Ntoumas K, Bolomitis S, Tyritzis SI, et al. (2012) The multi-cancer marker, rs6983267, located at region 3 of chromosome 8q24, is associated with prostate cancer in Greek patients but does not contribute to the aggressiveness of the disease. Clin Chem Lab Med 50: 379-385.
90. Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, et al. (2009) The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 41: 882-884.
91. Prokunina-Olsson L, Hall JL, (2009) No effect of cancer-associated SNP rs6983267 in the 8q24 region on co-expression of MYC and TCF7L2 in normal colon tissue. Mol Cancer 8: 96.
92. Perera PM, Wypasek E, Madhavan S, Rath-Deschner B, Liu J, et al. (2010) Mechanical signals control SOX-9, VEGF, and c-Myc expression and cell proliferation during inflammation via integrin-linked kinase, B-Raf, and ERK1/2-dependent signaling in articular chondrocytes. Arthritis Res Ther 12: R106.
93. Castellvi-Bel S, Ruiz-Ponte C, Fernandez-Rozadilla C, Abuli A, Munoz J, et al. (2012) Seeking genetic susceptibility variants for colorectal cancer: the EPICOLON consortium experience. Mutagenesis 27: 153-159.
94. Prenzel T, Kramer F, Bedi U, Nagarajan S, Beissbarth T, et al. (2012) Cohesin is required for expression of the estrogen receptor-alpha (ESR1) gene. Epigenetics Chromatin 5: 13.
95. Monnich M, Kuriger Z, Print CG, Horsfield JA, (2011) A zebrafish model of Roberts syndrome reveals that Esco2 depletion interferes with development by disrupting the cell cycle. PLoS One 6: e20051.
96. Chien R, Zeng W, Kawauchi S, Bender MA, Santos R, et al. (2011) Cohesin mediates chromatin interactions that regulate mammalian beta-globin expression. J Biol Chem 286: 17870-17878.
97. Sofueva S, Hadjur S (2012) Cohesin-mediated chromatin interactions-into the third dimension of gene regulation. Brief Funct Genomics.
98. Poleshko A, Einarson MB, Shalginskikh N, Zhang R, Adams PD, et al. (2010) Identification of a functional network of human epigenetic silencing factors. J Biol Chem 285: 422-433.
99. Acevedo ML, Kraus WL, (2003) Mediator and p300/CBP-steroid receptor coactivator complexes have distinct roles, but function synergistically, during estrogen receptor alpha-dependent transcription with chromatin templates. Mol Cell Biol 23: 335-348.
100. Kawazu M, Saso K, Tong KI, McQuire T, Goto K, et al. (2011) Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One 6: e17830.
101. Reid G, Gallais R, Metivier R, (2009) Marking time: the dynamic role of chromatin and covalent modification in transcription. Int J Biochem Cell Biol 41: 155-163.
102. Krumm A, Hickey LB, Groudine M, (1995) Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. Genes Dev 9: 559-572.
103. Fay A, Misulovin Z, Li J, Schaaf CA, Gause M, et al. (2011) Cohesin selectively binds and regulates genes with paused RNA polymerase. Curr Biol 21: 1624-1634.
104. Hopkins AL, Groom CR, (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730.
105. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, et al. (2011) Breast Cancer Special Feature: Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci U S A.
106. van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, van Agthoven TL, et al. (2010) Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer 17: 215-230.
107. Xu H, Yan M, Patra J, Natrajan R, Yan Y, et al. (2011) Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Res 13: R9.
108. Xu H, Balakrishnan K, Malaterre J, Beasley M, Yan Y, et al. (2010) Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in mice. PLoS One 5: e12112.
109. Laubstein H, Monnich HT, (1985) [Epidemiology of occupational dermatoses (IV)]. Dermatol Monatsschr 171: 2-13.